|Bid||150.40 x 100|
|Ask||150.99 x 100|
|Day's Range||146.21 - 152.35|
|52 Week Range||36.71 - 192.94|
|PE Ratio (TTM)||-17.69|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
The biotechnology-stock rally continues. The SPDR S&P Biotech (XBI) and the iShares Nasdaq Biotechnology (IBB), among the highest-flying exchange-traded funds yesterday, both hit their 52-week highs on ...
Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca.